Compare Aurobindo Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs IPCA LABS - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA IPCA LABS AUROBINDO PHARMA/
IPCA LABS
 
P/E (TTM) x 9.4 23.5 39.8% View Chart
P/BV x 1.7 4.5 38.4% View Chart
Dividend Yield % 0.6 0.3 226.1%  

Financials

 AUROBINDO PHARMA   IPCA LABS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
IPCA LABS
Mar-19
AUROBINDO PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs8301,042 79.7%   
Low Rs527590 89.3%   
Sales per share (Unadj.) Rs333.9298.6 111.8%  
Earnings per share (Unadj.) Rs40.435.0 115.3%  
Cash flow per share (Unadj.) Rs51.849.4 104.7%  
Dividends per share (Unadj.) Rs2.503.00 83.3%  
Dividend yield (eoy) %0.40.4 100.2%  
Book value per share (Unadj.) Rs237.1247.1 95.9%  
Shares outstanding (eoy) m585.91126.35 463.7%   
Bonus/Rights/Conversions ESOPESOS-  
Price / Sales ratio x2.02.7 74.4%   
Avg P/E ratio x16.823.3 72.1%  
P/CF ratio (eoy) x13.116.5 79.4%  
Price / Book Value ratio x2.93.3 86.7%  
Dividend payout %6.28.6 72.3%   
Avg Mkt Cap Rs m397,569103,108 385.6%   
No. of employees `00017.913.4 132.8%   
Total wages/salary Rs m25,8497,874 328.3%   
Avg. sales/employee Rs Th10,956.92,807.0 390.3%   
Avg. wages/employee Rs Th1,447.7585.8 247.1%   
Avg. net profit/employee Rs Th1,324.3329.0 402.5%   
INCOME DATA
Net Sales Rs m195,63637,732 518.5%  
Other income Rs m1,553577 269.3%   
Total revenues Rs m197,18938,309 514.7%   
Gross profit Rs m39,5196,901 572.7%  
Depreciation Rs m6,6801,824 366.2%   
Interest Rs m2,626189 1,391.6%   
Profit before tax Rs m31,7675,465 581.3%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2691,042 697.3%   
Profit after tax Rs m23,6454,422 534.7%  
Gross profit margin %20.218.3 110.5%  
Effective tax rate %22.919.1 119.9%   
Net profit margin %12.111.7 103.1%  
BALANCE SHEET DATA
Current assets Rs m153,64523,778 646.2%   
Current liabilities Rs m120,42910,975 1,097.3%   
Net working cap to sales %17.033.9 50.0%  
Current ratio x1.32.2 58.9%  
Inventory Days Days135104 130.3%  
Debtors Days Days6466 96.6%  
Net fixed assets Rs m103,90920,368 510.2%   
Share capital Rs m586253 231.9%   
"Free" reserves Rs m138,32230,971 446.6%   
Net worth Rs m138,90831,224 444.9%   
Long term debt Rs m1,8001,409 127.8%   
Total assets Rs m264,54445,507 581.3%  
Interest coverage x13.130.0 43.7%   
Debt to equity ratio x00 28.7%  
Sales to assets ratio x0.70.8 89.2%   
Return on assets %9.910.1 98.0%  
Return on equity %17.014.2 120.2%  
Return on capital %23.817.3 137.6%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m97,31617,308 562.2%   
Fx outflow Rs m40,5896,266 647.7%   
Net fx Rs m56,72711,042 513.7%   
CASH FLOW
From Operations Rs m16,2204,923 329.5%  
From Investments Rs m-28,768-1,563 1,840.5%  
From Financial Activity Rs m19,191-1,832 -1,047.5%  
Net Cashflow Rs m6,6561,528 435.7%  

Share Holding

Indian Promoters % 54.1 45.9 117.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 11.4 69.7%  
FIIs % 27.7 25.3 109.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 17.4 58.6%  
Shareholders   69,601 36,892 188.7%  
Pledged promoter(s) holding % 8.6 2.1 400.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   CIPLA  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Nov 15, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - VENUS REMEDIES COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS